All-solid-state Z-scheme photocatalysts,containing Cu_(2)O,TiO_(2)(rutile),and Au as the elec-tron mediator,were prepared and applied to the reduction of Cr(Ⅵ)in aqueous solutions.The Cu_(2)O-Au-TiO_(2) composites we...All-solid-state Z-scheme photocatalysts,containing Cu_(2)O,TiO_(2)(rutile),and Au as the elec-tron mediator,were prepared and applied to the reduction of Cr(Ⅵ)in aqueous solutions.The Cu_(2)O-Au-TiO_(2) composites were prepared by loading Au core-Cu_(2)O shell hemisphere particles on TiO_(2)(rutile)nanorods using a two-step photocatalytic deposition process.Un-der ultraviolet-visible(UV-vis)light illumination,the Cu_(2)O-Au-TiO_(2) composites exhibited higher photocatalytic Cr(Ⅵ)reduction activities than those exhibited by single TiO_(2)(rutile)and Cu_(2)O.In this reaction,a precipitate containing Cr,which was considered to be Cr(OH)_(3),was deposited site-selectively on the Au core-Cu_(2)O shell particles of the composites,indi-cating that the reduction site of the composite was Cu_(2)O,and the reaction proceeded accord-ing to the Z-scheme.The Cu_(2)O-Au-TiO_(2) composites also exhibited photocatalytic activity under visible light illumination.The oxidation state of Cu in the Cu_(2)O-Au-TiO_(2) composite gradually changed from Cu(Ⅰ)to Cu(Ⅱ)during the photocatalytic Cr(Ⅵ)reduction.However the composite maintained its high photocatalytic performance even after oxidation.The role of Au in the Cu_(2)O-Au-TiO_(2) composite was examined by comparing the properties of the Cu_(2)O-Au-TiO_(2) composite with those of the Cu_(2)O-TiO_(2) composite prepared via direct Cu_(2)O deposition on TiO_(2).展开更多
Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocum...Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electrophoresis method (3%PAGE), 2) 2% - 16% nondenatured poly-acrylamide gradient gel electro-phoresis method (2% - 16% GGE) and 3) 2.7% - 5% GGE. Evolocumab 140 mg/day administered together with statin significantly improved serum total cholesterol (TC), triglyceride (TG), high-dense lipoprotein-cholesterol (HDL-C), and LDL-C after four-week treatment. Results: TC, TG, HDL-C and LDL-C levels were improved by, respectively, 33%, 20%, 10%, and 54%. The mean LDL size significantly increased from 25.6 ± 0.4 nm to 26.4 ± 0.8 nm. The small dense LDL-cholesterol (sdLDL-C), large buoyant LDL-cholesterol (lbLDL-C), and mid-band lipoprotein-cholesterol were reduced, respectively. Therefore, the preliminary study on this paper can be the first step into a new insight on the world of lipid metabolism. Conclusion: Short-term administration of evolocumab addedons to statin therapy, significantly reduced small size LDL levels.展开更多
基金This work was supported by the Japan Society for the Promotion of Science(JSPS)KAKENHI(No.JP 19K05057).
文摘All-solid-state Z-scheme photocatalysts,containing Cu_(2)O,TiO_(2)(rutile),and Au as the elec-tron mediator,were prepared and applied to the reduction of Cr(Ⅵ)in aqueous solutions.The Cu_(2)O-Au-TiO_(2) composites were prepared by loading Au core-Cu_(2)O shell hemisphere particles on TiO_(2)(rutile)nanorods using a two-step photocatalytic deposition process.Un-der ultraviolet-visible(UV-vis)light illumination,the Cu_(2)O-Au-TiO_(2) composites exhibited higher photocatalytic Cr(Ⅵ)reduction activities than those exhibited by single TiO_(2)(rutile)and Cu_(2)O.In this reaction,a precipitate containing Cr,which was considered to be Cr(OH)_(3),was deposited site-selectively on the Au core-Cu_(2)O shell particles of the composites,indi-cating that the reduction site of the composite was Cu_(2)O,and the reaction proceeded accord-ing to the Z-scheme.The Cu_(2)O-Au-TiO_(2) composites also exhibited photocatalytic activity under visible light illumination.The oxidation state of Cu in the Cu_(2)O-Au-TiO_(2) composite gradually changed from Cu(Ⅰ)to Cu(Ⅱ)during the photocatalytic Cr(Ⅵ)reduction.However the composite maintained its high photocatalytic performance even after oxidation.The role of Au in the Cu_(2)O-Au-TiO_(2) composite was examined by comparing the properties of the Cu_(2)O-Au-TiO_(2) composite with those of the Cu_(2)O-TiO_(2) composite prepared via direct Cu_(2)O deposition on TiO_(2).
文摘Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electrophoresis method (3%PAGE), 2) 2% - 16% nondenatured poly-acrylamide gradient gel electro-phoresis method (2% - 16% GGE) and 3) 2.7% - 5% GGE. Evolocumab 140 mg/day administered together with statin significantly improved serum total cholesterol (TC), triglyceride (TG), high-dense lipoprotein-cholesterol (HDL-C), and LDL-C after four-week treatment. Results: TC, TG, HDL-C and LDL-C levels were improved by, respectively, 33%, 20%, 10%, and 54%. The mean LDL size significantly increased from 25.6 ± 0.4 nm to 26.4 ± 0.8 nm. The small dense LDL-cholesterol (sdLDL-C), large buoyant LDL-cholesterol (lbLDL-C), and mid-band lipoprotein-cholesterol were reduced, respectively. Therefore, the preliminary study on this paper can be the first step into a new insight on the world of lipid metabolism. Conclusion: Short-term administration of evolocumab addedons to statin therapy, significantly reduced small size LDL levels.
